Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,148.42
(
0.00%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: kamehameha post# 141875

Monday, 05/14/2012 11:36:44 AM

Monday, May 14, 2012 11:36:44 AM

Post# of 257580

VRTX/JAK class—[Biotech Jim]: initially starting with non-selective agents and then getting more selective…

[kamehameha]: that's why the JAK3 inhibitor VX-509 is a good bet!

It’s premature to say this, IMO. JAK3 specificity could turn out to be why VX-509 is a bad bat relative to the other JAK inhibitors in development.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today